Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...
Spending the day facing the challenges of kidney patients helps workers at a CT pharmaceutical company understand disease and ...
Boehringer Ingelheim has halted development of an obesity drug from Gubra that it originally pledged to advance back in 2017, ...
Privately-held German drugmaker Boehringer Ingelheim and researchers from the Stanley Center for Psychiatric Research at the ...
Ingelheim: Boehringer Ingelheim and researchers from the Stanley Center for Psychiatric Research at the Broad Institute of ...
The state-of-the-art research and development center in Georgia will help improve the health and wellbeing of animals ...
Substantial enrollment progress in Phase 1b trial of SZN-043 in severe alcohol-associated hepatitis patients with proof-of-concept data expected ...
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity.
Abdulla also aims to further strengthen relationships with regional governments and key healthcare stakeholders to ensure ...
No. 49 / 2024Zealand Pharma Announces Financial Results for the First Nine Months of 2024Continued strong progress across ...
Junior Professor Johannes Walker, University of Göttingen, has been awarded an Exploration Grant from the Boehringer Ingelheim Foundation. Walker teaches and carries out research at the Institute for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback